Development of a COVID Vaccine Model in NHP

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: ROBERT A SEDER
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2020
Award: $350,000
Funding agency: National Institute of Allergy and Infectious Diseases

NHP immunized with 10 and 100g of mRNA-1273 encoding the SARS CoV2 had robust neutralizing antibodiy titers following two immunizations.  mRNA-1273 induced Th1-biased CD4 T cell responses and low or undetectable Th2 or CD8 T responses.  Following an infectious challenge with SARS CoV2 by the intranasal (IN) or intratracheal route (IT), there is no detectable viral replication in the bronchoalveolar lavage (BAL) by day 2 following challenge in 7 out of 8 NHPs, in both 10 and 100 g mRNA-1273-immunized groups and no detectable viral replication in nasal swabs (NS) of all 8 NHPs immunized with 100 g mRNA-1273 by day 2 post-challenge. There was limited inflammation and no detectable virus in the lungs of either vaccine group.  mRNA-1273 vaccination induces robust SARS CoV-2 S neutralizing activity and rapid protection in the upper and lower airways with absence of lung immunopathology in NHP.

Terms: <2019 novel coronavirus><2019-nCoV><Adenoviridae><Adenoviruses><Antibody Response><Bronchioalveolar Lavage><Bronchoalveolar Lavage><Bronchopulmonary Lavage><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8B><CD8B1><CD8B1 gene><COVID><COVID-19><COVID19><Cell membrane><Chimera Protein><Chimeric Proteins><CoV disease><Cytoplasmic Membrane><DNA><Deoxyribonucleic Acid><Development><Formulation><Fusion Protein><Goals><Health Priorities><Human><Immune><Immunes><Immunization><Immunize><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunostimulation><Infection><Inflammation><LYT3><Lung><Lung Lavage><Lung Respiratory System><Membrane Fusion><Messenger RNA><Modeling><Modern Man><Nasal><Nasal Passages Nose><Non-Polyadenylated RNA><Nose><Nucleic Acid Vaccines><Plasma Membrane><Protein Subunits><Proteins><RNA><RNA Gene Products><RNA vaccine><Respiratory System, Nose, Nasal Passages><Ribonucleic Acid><Route><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><Swab><T cell response><T4 Cells><T4 Lymphocytes><Vaccination><Vaccines><Viral><Virus><Virus Replication><Wuhan coronavirus><bronchopulmonary lavage therapy><corona virus disease><corona virus disease 2019><coronavirus disease><coronavirus disease 2019><develop a vaccine><development of a vaccine><developmental><global health><immunogenicity><immunopathology><mRNA><mRNA vaccine><pandemic><pandemic disease><plasmalemma><pulmonary><receptor binding><receptor bound><response><vaccine candidate><vaccine development><vaccine formulation><viral multiplication><viral replication><virus multiplication>